Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia

References

• Hernandez JA, Land KJ, McKenna RW. Leukemias, myeloma, and other lymphoreticular neoplasms. Cancer 1995;75:381–94.
   PubMed Web of Science ®Google Scholar
• Surveillance Epidemiology and End Results (SEER) Stat Fact Sheets: Chronic lymphocytic leukemia [Internet]. April 2011. Available from: http://seer.cancer.gov/statfacts/html/clyl.html
   Google Scholar
• Brenner H, Gondos A, Pulte D. Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century. Blood 2008;111:4916–4921.
   PubMed Web of Science ®Google Scholar
• Hartmann T, Pleyer L, Desch P, . Novel therapeutics approaches to chronic lymphocytic leukemia based on recent biological insights. Discov Med 2009;8:157–164.
   PubMedGoogle Scholar
• Maddocks K, Lin T. Update in the management of chronic lymphocytic leukemia. J Hematol Oncol 2009;2:29.
   PubMedGoogle Scholar
• Pleyer L, Egle A, Hartmann T, . Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat Rev Clin Oncol 2009;6:405–418.
   PubMed Web of Science ®Google Scholar
• Rai K, Keating M. Initial treatment of chronic lymphocytic leukemia. Basow DS. UpToDate. Waltham, MA: UpToDate; 2009.
   Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, . Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164–1174.
   PubMed Web of Science ®Google Scholar
• Greenberg D, Earle C, Fang CH, . When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. J Natl Cancer Inst 2010;102:82–88.
   PubMed Web of Science ®Google Scholar
• Meropol NJ, Schrag D, Smith TJ, . American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol 2009;27:3868–3874.
   PubMed Web of Science ®Google Scholar
• Stram M, Taberkiewicz J, Hus I, . New approaches in treatment of B-cell chronic lymphocytic leukemia. Cancer Ther 2009;7:163–173.
   Google Scholar
• Weinstein MC. Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics 2006;24:1043–1053.
   PubMed Web of Science ®Google Scholar
• Tam C, O'Brien S, Wierda W, . Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112:975–980.
   PubMed Web of Science ®Google Scholar
• Arias E. National Vital Statistics Report [Internet]. November 2010. Available from: http://www.cdc.gov/nchs/data/nvsr/nvsr58/nvsr58_21.pdf
   Google Scholar
• Hornberger J, Reyes C, Lubeck D, . Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma. Leuk Lymphoma 2008;49:227–236.
   Google Scholar
• Centers for Medicare & Medicaid Services Physician Fee Schedule [Internet]. Baltimore, MD: CMS; June 2009. Available from: http://www.cms.gov/
   Google Scholar
• Byrd J, Murphy T, Howard R, . Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001;19:2153–2164.
   PubMed Web of Science ®Google Scholar
• Castro JE, Sandoval-Sus JD, Bole J, . Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia 2008;22:2048–2053.
   PubMed Web of Science ®Google Scholar
• Dungarwalla M, Evans S, Riley U, . High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologica 2008;93:475–476.
   PubMed Web of Science ®Google Scholar
• Robak T, Dmoszynska A, Solal-Celigny P, . Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010;28:1756–1765.
   PubMed Web of Science ®Google Scholar
• Robak T, Smolewski P, Cebula B, . Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia. Eur J Haematol 2007;79:107–113.
   PubMed Web of Science ®Google Scholar
• Winkler U, Jensen M, Manzke O, . Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999;94:2217–2224.
   PubMed Web of Science ®Google Scholar
• Woyach J, Lin T, Lucas M, . A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. Leukemia 2009;23:912–918.
   Google Scholar
• Hassett MJ. The full burden of cancer. Oncologist 2010;15: 793–795.
   PubMed Web of Science ®Google Scholar
• Van Houtven CH, Ramsey SD, Hornbrook MC, . Economic burden for informal caregivers of lung and colorectal cancer patients. Oncologist 2010;15:883–893.
   PubMed Web of Science ®Google Scholar
• Szafran R. Age-adjusted labor force participation rates, 1960-2045 [Internet]. 2002. Available from: http://www.bls.gov/opub/mlr/2002/09/art3full.pdf
   Google Scholar
• May 2009 National occupational employment and wage estimates, United States. Bureau of Labor Statistics [Internet]. 2009. Available from: http://www.bls.gov/oes/current/oes_nat.htm#00-0000
   Google Scholar
• Overview of BLS statistics on inflation and prices [Internet]. 2010. Available from: http://www.bls.gov/bls/inflation.htm
   Google Scholar
• Weinstein MC, O'Brien B, Hornberger J, . Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices—Modeling Studies. Value Health 2003;6:9–17.
   PubMed Web of Science ®Google Scholar
• Lipscomb J, Weinstein M, Torrance G. Time preference. Gold MR, Siegel JE, Russell LB, . Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996. 214–246.
   Google Scholar
• Beusterien KM, Davies J, Leach M, . Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study. Health Qual Life Outcomes 2010;8:50.
   PubMed Web of Science ®Google Scholar
• Basu A, Meltzer D. Implications of spillover effects within the family for medical cost-effectiveness analysis. J Health Econ 2005;24:751–773.
   PubMed Web of Science ®Google Scholar
• Basu A, Dale W, Elstein A, . A time tradeoff method for eliciting partner's quality of life due to patient's health states in prostate cancer. Med Decis Making 2010;30:355–365.
   PubMed Web of Science ®Google Scholar
• Bennett CL, Golub R, Waters TM, . Economic analyses of phase III cooperative cancer group clinical trials: are they feasible? Cancer Invest 1997;15:227–236.
   PubMed Web of Science ®Google Scholar
• Bennett CL, Waters TM. Economic analyses in clinical trials for cooperative groups: operational considerations. Cancer Invest 1997;15:448–453.
   PubMed Web of Science ®Google Scholar
• Ramsey S, Willke R, Briggs A, . Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health 2005 8:521–533.
   PubMed Web of Science ®Google Scholar
• Amend KL, Turnbull B, Foskett N, . Incidence of progressive multifocal leukoencephalopathy in patients without HIV. Neurology 2010;75:1326–1332.
   PubMed Web of Science ®Google Scholar
• Carson KR, Evens AM, Richey EA, . Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009;113:4834–4840.
   PubMed Web of Science ®Google Scholar
• Carson KR, Focosi D, Major EO, . Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009;10:816–824.
   PubMed Web of Science ®Google Scholar
• D'Souza A, Wilson J, Mukherjee S, . Progressive multifocal leukoencephalopathy in chronic lyhmphocytic leukemia: a report of three cases and review of the literature. Clin Lymphoma Myeloma Leuk 2010;10:E1–E9.
   PubMed Web of Science ®Google Scholar
• Carr E, Lerner S, Aultman R, . Treatment effect of first line rituximab, fludarabine and cyclosphosphamide in a chronic lymphocytic leukemia patient cohort: an evaluation of prognostic factors, estimated life expectancy and economic outcomes. Blood 2008;112(Suppl. 1): Abstract 2396.
   Google Scholar
• Rituximab for the first-line treatment of chronic lymphocytic leukaemia. National Institute for Health and Clinical Excellence [Internet]. November 2009. Available from: http://www.nice.org.uk/nicemedia/live/11907/44906/44906.pdf
   Google Scholar
• Fludarabine, cyclophosphamide, and rituximab or bendamustine and rituximab in treating patients with previously untreated B-cell chronic lymphocytic leukemia [Internet]. February 2009. Available from: http://clinicaltrials.gov/ct2/show/NCT00769522/
   Google Scholar